Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging

Fang, Junyong; Metter, E. Jeffrey; Landis, Patricia; Chan, Daniel W.; Morrell, Christopher H.; Carter, H.Ballentine

doi:10.1016/s0090-4295(01)01304-8

Cited by 164 publications

(97 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sensitivity, however, dropped to 11% in patients with PSA below 4.0 ng/mL. More recently, cutoffs of 0.1-0.5 ng/mL per year were proposed to recommend prostate biopsy for men within this PSA range (27). As high PSAV is rare when PSA levels are low, further studies are needed to evaluate PSAV cutoff with low PSA levels.…”

Section: Psa Velocity and Psa Doubling Timementioning

confidence: 99%

Prostatic specific antigen for prostate cancer detection

Nogueira¹,

Corradi²,

Eastham³

2009

Int. braz j urol.

View full text Add to dashboard Cite

Prostate-specific antigen (PSA) has been used for prostate cancer detection since 1994. PSA testing has revolutionized our ability to diagnose, treat, and follow-up patients. In the last two decades, PSA screening has led to a substantial increase in the incidence of prostate cancer (PC). This increased detection caused the incidence of advanced-stage disease to decrease at a dramatic rate, and most newly diagnosed PC today are localized tumors with a high probability of cure. PSA screening is associated with a 75% reduction in the proportion of men who now present with metastatic disease and a 32.5% reduction in the age-adjusted prostate cancer mortality rate through 2003. Although PSA is not a perfect marker, PSA testing has limited specificity for prostate cancer detection, and its appropriate clinical application remains a topic of debate. Due to its widespread use and increased over-detection, the result has been the occurrence of over-treatment of indolent cancers. Accordingly, several variations as regards PSA measurement have emerged as useful adjuncts for prostate cancer screening. These procedures take into consideration additional factors, such as the proportion of different PSA isoforms (free PSA, complexed PSA, pro-PSA and B PSA), the prostate volume (PSA density), and the rate of change in PSA levels over time (PSA velocity or PSA doubling time). The history and evidence underlying each of these parameters are reviewed in the following article.

show abstract

Section: Psa Velocity and Psa Doubling Timementioning

confidence: 99%

Prostatic specific antigen for prostate cancer detection

Nogueira¹,

Corradi²,

Eastham³

2009

Int. braz j urol.

View full text Add to dashboard Cite

show abstract

“…Significantly, this study found a threefold higher risk for prostate cancer within 10 to 25 years if PSA was greater than the median for the patient's age group. 44 For patients screened in their 50s, a baseline PSA value between the age-specific median and 2.5 ng/mL was associated with a 7.6-fold higher risk for prostate cancer. 45 Autopsy studies have shown that histologic evidence of prostate cancer is present in approximately 25% of men in the fourth decade of life, and the Surveillance Epidemiology and End Results (SEER) database shows that prostate cancer deaths begin to appear in men in their 40s.…”

Section: Effect Of Medication and Herbal Supplements On Tpsamentioning

confidence: 92%

Prostate Cancer Early Detection

Kawachi¹,

Bahnson²,

Barry³

et al. 2010

J Natl Compr Canc Netw

118

View full text Add to dashboard Cite

240The NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection (to view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org) provide a set of sequential recommendations detailing a screening and subsequent workup strategy for maximizing the detection of prostate cancer in an early, organconfined state and attempting to minimize unnecessary procedures. These guidelines were developed for men who have elected to participate in prostate cancer screening; they are not meant to address the controversy regarding population screening. OverviewProstate cancer is the most commonly diagnosed NCCN Categories of Evidence and ConsensusCategory 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus. Category 2A: The recommendation is based on lowerlevel evidence and there is uniform NCCN consensus. Category 2B: The recommendation is based on lowerlevel evidence and there is nonuniform NCCN consensus (but no major disagreement). Category 3: The recommendation is based on any level of evidence but reflects major disagreement. Please NoteThese guidelines are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way.These guidelines are copyrighted by the National Comprehensive Cancer Network. All rights reserved. These guidelines and the illustrations herein may not be reproduced in any form without the express written permission of the NCCN © 2010. Disclosures for the NCCN Prostate Cancer Early Detection Guidelines PanelAt the beginning of each NCCN guidelines panel meeting, panel members disclosed any financial support they have received from industry. Through 2008, this information was published in an aggregate statement in JNCCN and online. Furthering NCCN's commitment to public transparency, this disclosure process has now been expanded by listing all potential conflicts of interest respective to each individual expert panel member. cancer and the second leading cause of cancer death in American men. More than 192,000 men will be diagnosed with prostate cancer in 2009, and an estimated 27,360 men will die of this disease. 1During the same period, nearly 20 million men in the United States will be confronted with important decisions regarding early detection for prostate cancer. Men in the United States have an approximately 1 in 6 chance of eventually being diagnosed with this malignancy and about 1 in 30 chance of eventually dying of it.2 African-American men and men with a first-degree relative with prostate cancer (especially cancer fo...

show abstract

“…Initial PSA and risk of clinically significant disease have been investigated, since several studies have identified absolute threshold values to predict risk of subsequent diagnosis [47][48][49][50]. Investigators from the Malmö Preventive Project, within a case-control nested analysis, found that PSA levels at age 60 predicted lifetime risk of clinically significant prostate cancer, since men whose initial PSA was below the median (1.06 ng/mL) had 0.5 % risk of metastasis by age 85 and 0.2 % risk of death from prostate cancer, suggesting little benefit to regular screening every 1 or 2 years in these men [51••].…”

Section: Psamentioning

confidence: 99%

Risk-Based Prostate Cancer Screening: Who and How?

2013

View full text Add to dashboard Cite

The purpose of this review is to identify clinical risk factors for prostate cancer and to assess the utility and limitations of our current tools for prostate cancer screening. Prostate-specific antigen is the single most important factor for identifying men at increased risk of prostate cancer but is best assessed in the context of other clinical factors; increasing age, race, and family history are well-established risk factors for the diagnosis of prostate cancer. In addition to clinical risk calculators, novel tools such as multiparametric imaging, serum or urinary biomarkers, and genetic profiling show promise in improving prostate cancer diagnosis and characterization. Optimal use of existing and future tools will help alleviate the problems of overdiagnosis and overtreatment of low-risk prostate cancer without reversing the substantial mortality declines that have been achieved in the screening era.

show abstract

Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging

Cited by 164 publications

References 14 publications

Prostatic specific antigen for prostate cancer detection

Prostatic specific antigen for prostate cancer detection

Prostate Cancer Early Detection

Risk-Based Prostate Cancer Screening: Who and How?

Contact Info

Product

Resources

About